<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>ABSTRACT: INTRODUCTION: <z:chebi fb="0" ids="50114">Estrogen</z:chebi> Receptor- (ER) and Human Epidermal Growth Factor Receptor 2 (HER2) positivity are inversely correlated by standard criteria </plain></SENT>
<SENT sid="1" pm="."><plain>However, we investigated the quantitative relationship between ER and HER2 expression at both <z:chebi fb="40" ids="33697">RNA</z:chebi> and protein levels in HER2+ve and HER2-ve <z:hpo ids='HP_0003002'>breast carcinomas</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: ER and HER2 levels were assessed by immunohistochemistry (IHC) and (for HER2) Fluorescent In Situ Hybridization (FISH) and by q-RT-PCR in formalin-fixed primary <z:hpo ids='HP_0003002'>breast cancers</z:hpo> from 448 patients in the National <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Research Institute (NCRI) Adjuvant <z:hpo ids='HP_0003002'>Breast Cancer</z:hpo> Trial (ABC) <z:chebi fb="3" ids="41774">tamoxifen</z:chebi> only arm </plain></SENT>
<SENT sid="3" pm="."><plain>Relationships at the <z:chebi fb="40" ids="33697">RNA</z:chebi> level were assessed in 1139 TransATAC <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: ER and HER2 <z:chebi fb="40" ids="33697">RNA</z:chebi> levels were negatively correlated as expected in HER2+ve (IHC 3+ and/or FISH-amplified) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> (r=-0.45, P=0.0028) </plain></SENT>
<SENT sid="5" pm="."><plain>However in HER2-ve <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> (ER+ve and ER-ve combined), a significant positive correlation was found (r=0.43, P&lt;0.0001), HER2 <z:chebi fb="40" ids="33697">RNA</z:chebi> levels being 1.74-fold higher in ER+ve vs. ER-ve <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>This correlation was maintained in the ER+veHER2-ve subgroup (r=0.24, P=0.0023) and confirmed in this subgroup in 1139 TransATAC <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> (r=0.25, P&lt;0.0001) </plain></SENT>
<SENT sid="7" pm="."><plain>The positive relationship extended to IHC-detected ER in ABC: mean+/-95%CI H-scores were 90+/-19 and 134+/-19 for 0 and 1+ HER2 IHC categories, respectively (P=0.0013) </plain></SENT>
<SENT sid="8" pm="."><plain>A trend towards lower <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e> was observed in patients with the lowest levels of ER and HER2 <z:chebi fb="40" ids="33697">RNA</z:chebi> levels within the ER+veHER2-ve subgroup both for ABC and TransATAC cohorts </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: ER and HER2 expression is positively correlated in HER2ve <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>The distinction between HER2+ve and HER2ve is greater in ERve than ER+ve <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>These findings are important to consider in clinical trials of anti-HER2 and anti-<z:chebi fb="32" ids="24621">endocrine</z:chebi> therapy in HER2ve disease </plain></SENT>
<SENT sid="12" pm="."><plain>Clinical trial identifier: ISRCTN31514446 </plain></SENT>
</text></document>